Amendment of Schedule 1 (further provisions for classification of medicinal products)U.K.
This section has no associated Explanatory Memorandum
[F18. In Schedule 1—
(a)in paragraph 1—
(i)in sub-paragraph (b), insert “UK” before “marketing authorisation”;
(ii)in sub-paragraphs (e)(i), (f)(i) and (g)(i), for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation, Article 126a authorisation or parallel import licence”; and
(b)in paragraph 4, for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation, Article 126a authorisation, parallel import licence”.]
Textual Amendments
F1Reg. 8 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 5